Research Projects & Grants

College/University

  • POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: Investigator, Duke University, (12/2024 - 12/2025) Status: Approved

For Profit Organization

  • SWOG-S0820: A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III - preventing adenomas of the colon with eflornithine and sulindac (PACES), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • SWOG-A081105: randomized study of Erlotinib VS Observation in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-small Cell Lung Cancer (NSCLC), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • Amgen 20190135: A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (plNN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation, Role: Investigator, Amgen, Inc., (02/2025 - 02/2026) Status: Approved
  • SWOG S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3457 (Pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with = 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
  • SWOG S1316: Prospective comparative effectiveness trial for malignant bowel obstruction, Role: Investigator, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
  • ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, Atara Biotherapeutics, Inc., (12/2024 - 12/2025) Status: Approved
  • Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
  • SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers, Role: Investigator, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
  • SWOG-S1216: a phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer, Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • SWOG A151216: adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST), Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors, Role: Investigator, Apollomics Inc., (09/2024 - 09/2025) Status: Approved
  • EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas, Role: Investigator, Oncoceutics, Inc., (10/2022 - 10/2023) Status: Completed
  • Astellas 8951-CL-0301: A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, Role: Investigator, Astellas Pharma US, Inc., (06/2022 - 06/2023) Status: Completed
  • C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2), Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (07/2021 - 07/2022) Status: Completed
  • Novartis CACZ885V2301: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2), Role: Investigator, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
  • SWOG -EAY131: Molecular analysis for therapy choice (MATCH), Role: Investigator, Southwest Oncology Group, (08/2019 - 08/2020) Status: Completed
  • SWOG/NRG LU003: A Biomarker-Driven protocol for previously treated ALK-Positive Non-Squamous NSCLC patients: The NCI-NRG ALK protocol, Role: Investigator, Southwest Oncology Group, Status: Completed
  • SWOG A041701: A randomized phase II/III study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute Myeloid Leukemia receiving intensive induction chemotherapy, Role: PI, Southwest Oncology Group, Status: Completed
  • Managed Access Programs (MAP) CTL019B2003I, Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2025 - 01/2026) Status: Approved

Internal

  • Retrospective Analysis of Cerebrospinal Fluid in Patients with Hematologic Malignancies Performed at Loma Linda Medical Center from 01/01/2010-12/31/2023 in Adult and Pediatric Patients, Role: PI, LLU Dept. of Medicine, (02/2024) Status: Approved
  • Predictors for antibody formation and clinical outcomes in COVID-19 infections in Oncology patients, Role: PI, LLU Dept. of Medicine, (03/2022) Status: Approved
  • Zinc and Copper Deficiency's Association with Chronic Anemia, Role: PI, LLU Dept. of Medicine, (03/2022) Status: Approved
  • Outcomes including complete vs partial response rate and toxicity profile of Blinatumomab in patient with B-cell acute lymphocytic (B-ALL) at a tertiary medical center, Role: PI, LLU Dept. of Medicine, (01/2022) Status: Approved
  • Investigator Initiated: A Retrospective chart review of patients treated with immune checkpoint inhibitors (ICI) to evaluate severe and fatal adverse events in the emergency department, Role: Investigator, LLU Dept. of Pharmacy Practice, (07/2021 - 10/2024) Status: Completed
  • Investigator Initiated DLBCL: Retrospective analysis of CNS relapse in patients with diffuse large B cell lymphoma with high CNS IPI scores with or without prophylactic treatment-A single institution study, Role: PI, LLU Dept. of Medicine, (06/2021) Status: Approved
  • Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Correlation Study of Serologic Anti-SARS-CoV-2 antibody to Treatment Efficacy and Outcome, Role: Investigator, LLU Basic Science, (06/2020) Status: Approved
  • Defibrotide prophylaxis in pediatric and adult hematopoietic stem cell transplant recipients: A Retrospective Chart Review (NYMC-217), Role: Investigator, LLU Dept. of Medicine, (07/2024) Status: Approved
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved
  • Retrospective Analysis of Manganese Deficiency and Anemia at Loma Linda Medical Center from 1/1/2020 – 12/31/2024, Role: PI, LLU Cancer Institute, (03/2025) Status: Approved
  • Retrospective Analysis of EASIX Score for Prognostication of Newly Diagnosed Hematologic Malignancies at Loma Linda Medical Center from 1/1/2010 – 12/31/2024, Role: PI, LLU Cancer Institute, (03/2025) Status: Approved

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: Investigator, Pediatric Blood and Marrow Transplant Consortium, (06/2024 - 06/2025) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: Investigator, National Marrow Donor Program, (06/2024 - 06/2025) Status: Approved
  • National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved